Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jayesh Desai

Showing results (61-70 of 179) with videos related to

Pageof 18
Sort By:
Targeted Oncology|February 18, 2021
BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?Vanessa Wong, Margaret Lee, Rachel Wong, et al.
Contemporary Clinical Trials Communications|October 26, 2019
First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)Toan Pham, Lloyd Pereira, Sara Roth, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 6, 2022
The benefit for radiotherapy at specialised sarcoma centres: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma AssociationAngela M Hong, Helen Lo, Anna Lawless, et al.
Journal of Surgical Oncology|October 21, 2020
Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapyHayden Snow, Catherine Mitchell, Shona Hendry, et al.
Asia-Pacific Journal of Clinical Oncology|June 26, 2024
Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012-2022Nadia Hitchen, Adel Shahnam, Sathya Manoharan, et al.
International Journal of Cancer|April 25, 2009
Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthoodKenneth K Khamly, Vicky J Thursfield, Michael Fay, et al.
Targeted Oncology|August 28, 2015
First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid TumorsRodrigo Dienstmann, Ulrik Lassen, Jonathan Cebon, et al.
Clinical Colorectal Cancer|November 10, 2016
Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal AdenocarcinomaRebecca Y Tay, Murtaza Jamnagerwalla, Malcolm Steel, et al.
Pathology|December 13, 2025
The value of a second expert opinion in histopathological diagnosis of bone and soft tissue sarcoma: a systematic reviewJennifer Vu, Claudia Petrucco, Cristina Vargas, et al.
Investigational New Drugs|May 17, 2018
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancersAflah Roohullah, Adam Cooper, Anna J Lomax, et al.
Pageof 18

Showing results (61-70 of 179) with videos related to

Sort By:
Pageof 18
Targeted Oncology|February 18, 2021
BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?Vanessa Wong, Margaret Lee, Rachel Wong, et al.
Contemporary Clinical Trials Communications|October 26, 2019
First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)Toan Pham, Lloyd Pereira, Sara Roth, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 6, 2022
The benefit for radiotherapy at specialised sarcoma centres: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma AssociationAngela M Hong, Helen Lo, Anna Lawless, et al.
Journal of Surgical Oncology|October 21, 2020
Characterising the immune microenvironment in liposarcoma, its impact on prognosis and the impact of radiotherapyHayden Snow, Catherine Mitchell, Shona Hendry, et al.
Asia-Pacific Journal of Clinical Oncology|June 26, 2024
Trends in phase 1 oncology clinical trials across Australia; Analysis of ClinicalTrials.gov 2012-2022Nadia Hitchen, Adel Shahnam, Sathya Manoharan, et al.
International Journal of Cancer|April 25, 2009
Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthoodKenneth K Khamly, Vicky J Thursfield, Michael Fay, et al.
Targeted Oncology|August 28, 2015
First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid TumorsRodrigo Dienstmann, Ulrik Lassen, Jonathan Cebon, et al.
Clinical Colorectal Cancer|November 10, 2016
Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal AdenocarcinomaRebecca Y Tay, Murtaza Jamnagerwalla, Malcolm Steel, et al.
Pathology|December 13, 2025
The value of a second expert opinion in histopathological diagnosis of bone and soft tissue sarcoma: a systematic reviewJennifer Vu, Claudia Petrucco, Cristina Vargas, et al.
Investigational New Drugs|May 17, 2018
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancersAflah Roohullah, Adam Cooper, Anna J Lomax, et al.
Pageof 18